Long-term registry of adults with generalized myasthenia gravis treated with C5 inhibitors
Collects long-term data on safety and outcomes in adults with generalized myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Key facts
- Where
- Augusta, Birmingham, Boston, Burlington, Chapel Hill, Charlotte, Chattanooga, Clearwater, Colorado Springs, Columbia, Dallas, Dayton, Durham, Fort Collins, Fresno, Gainesville, Houston, Iowa City, Jacksonville, Knoxville, Lansing, Lexington, Milwaukee, New Haven, New Hyde Park, Orange, Philadelphia, Rancho Mirage, Scottsdale, Sylmar, Tampa, and Washington D.C., United StatesSee the 32 sites
Where in United States
- AugustaAugusta, United StatesTaking people
- BirminghamBirmingham, United StatesTaking people
- BostonBoston, United StatesTaking people
- BurlingtonBurlington, United StatesTaking people
- Chapel HillChapel Hill, United StatesTaking people
- CharlotteCharlotte, United StatesTaking people
- ChattanoogaChattanooga, United StatesTaking people
- ClearwaterClearwater, United StatesTaking people
- Colorado SpringsColorado Springs, United StatesTaking people
- ColumbiaColumbia, United StatesTaking people
- DallasDallas, United StatesTaking people
- DaytonDayton, United StatesTaking people
- DurhamDurham, United StatesTaking people
- Fort CollinsFort Collins, United StatesTaking people
- FresnoFresno, United StatesTaking people
- GainesvilleGainesville, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Iowa CityIowa City, United StatesTaking people
- JacksonvilleJacksonville, United StatesTaking people
- KnoxvilleKnoxville, United StatesTaking people
- LansingLansing, United StatesTaking people
- LexingtonLexington, United StatesTaking people
- MilwaukeeMilwaukee, United StatesTaking people
- New HavenNew Haven, United StatesTaking people
- New Hyde ParkNew Hyde Park, United StatesTaking people
- OrangeOrange, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
- Rancho MirageRancho Mirage, United StatesTaking people
- ScottsdaleScottsdale, United StatesTaking people
- SylmarSylmar, United StatesTaking people
- TampaTampa, United StatesTaking people
- Washington D.C.Washington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Trial code
- NCT04202341
- Record updated
- 18 February 2026
- Original description
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).Read full original descriptionShow less
Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Inclusion: Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment; Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions; Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry.
Exclusion: Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.